1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Jun 2024
Admin
News Article

Larimar Therapeutics Receives FDA Nod to Join START Pilot Program for Nomlabofusp

Larimar Therapeutics Receives FDA Nod to Join START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

Overview

Larimar Therapeutics, Inc. (Nasdaq: LRMR), a company in the biotechnology sector focusing on rare diseases, has announced that the FDA has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. Nomlabofusp is a novel protein therapy designed for the treatment of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria, targeting the root cause of the disease. The selection for the START program was based on nomlabofusp's readiness for development, its potential to address the significant medical needs in FA, alignment of development timelines, and a proposed communication strategy to expedite pivotal study initiation and potential Biologics License Application (BLA) submission.

Start Pilot Program

The START pilot program, initiated by the FDA in September 2023, aims to accelerate drug development, initially selecting up to six novel drugs, three each by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), to address rare diseases or other serious conditions with high unmet needs.
Sponsors selected for START benefit from more frequent and rapid interactions with the FDA to facilitate development towards pivotal clinical studies or pre-BLA meetings, aiming for high-quality data to support a BLA or New Drug Application (NDA).

Words from CMO: Larimar

Larimar, expressed enthusiasm about nomlabofusp's selection, emphasizing the FDA's commitment to accelerating development through enhanced communication. Dr. Russell Clayton, Larimar's Chief Medical Officer, highlighted the importance of increased FDA communication in progressing nomlabofusp's development, particularly for patients with FA.

Nomlabofusp is currently undergoing evaluation in an ongoing open-label extension study to assess long-term safety, pharmacokinetics, and frataxin levels in FA patients. Interim data is expected in Q4 2024.

Nomlabofusp

Nomlabofusp is a recombinant fusion protein designed to deliver human frataxin to mitochondria in FA patients.
It has received various designations from regulatory bodies, including Rare Pediatric Disease, Fast Track, and Orphan Drug designations from the FDA, Orphan Drug Designation from the European Commission, and PRIME designation from the European Medicines Agency.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!